多发性骨髓瘤中获得性1q22扩增的预后意义
该研究纳入Mayo Clinic 2004至2019年63例诊断时无1q22扩增但随访中获得性1q22扩增的多发性骨髓瘤患者,与63例未获得1q22扩增对照及126例诊断时即存在1q22扩增患者比较。获得性1q22扩增发生率为6.1%,中位获得时间5.0年;获得性1q22扩增患者中位总生存10.9年,低于对照的13.0年(p=.03),但高于诊断时即存在1q22扩增者的6.3年(p=.01)。
要点
- 获得性1q22扩增发生率为6.1%,中位获得时间5.0年。
- 获得性1q22扩增与总生存缩短相关(10.9年 vs 对照13.0年,p=.03)。
- 基线高危FISH增加1q22扩增获得风险,高危患者可考虑风险适应策略或临床试验。
核心结论
- 获得性1q22扩增是多发性骨髓瘤中显著的分子事件,与总生存缩短相关。
研究设计与样本
- 回顾性研究纳入Mayo Clinic 2004年1月至2019年12月63例诊断时无1q22扩增但随访中获得性1q22扩增的多发性骨髓瘤患者。
- 对照为63例随访相似但未获得1q22扩增的患者,另与126例诊断时即存在1q22扩增的患者比较。
主要发现
- 获得性1q22扩增发生率为6.1%(中位随访6.8年),中位获得时间5.0年(范围0.7-11.5年)。
- 基线FISH异常包括三体(54%)和单体13(39%);16例(25%)有高危易位或del(17p)。
- 一线治疗中位无进展生存:获得性1q22扩增组29.5个月,对照组31.4个月(p=.34),诊断时即存在1q22扩增组31.2个月(p=.04)。
- 自诊断起中位总生存:获得性1q22扩增组10.9年,对照组13.0年(p=.03),诊断时即存在1q22扩增组6.3年(p=.01)。
- 基线存在高危FISH增加1q22扩增获得风险。
临床怎么用
- 对多发性骨髓瘤患者应关注1q22扩增的获得性克隆演变,尤其基线高危FISH患者。
- 发生获得性1q22扩增的高危患者可考虑风险适应策略和/或临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gain of 1q22 at diagnosis portends poorer outcomes in multiple myeloma (MM), but the prognostic significance of acquired 1q22 gain is unknown. We identified 63 MM patients seen at Mayo Clinic from 1/2004 to 12/2019 without 1q22 gain at diagnosis who acquired it during follow up and compared them to 63 control patients who did not acquire 1q22 gain with similar follow up. We also compared outcomes in the acquired 1q22 gain group with outcomes in 126 patients with 1q22 gain present at diagnosis. The incidence of acquired 1q22 gain was 6.1% (median follow-up 6.8 years); median time to acquisition was 5.0 years (range: 0.7-11.5 years). Abnormalities on baseline fluorescence in situ hybridization (FISH) included trisomies (54%) and monosomy 13 (39%); 16 (25%) had high-risk (HR) translocations or del(17p). Median progression-free survival with front line therapy was 29.5 months in patients with acquired 1q22 gain, versus 31.4 months in control patients (p = .34) and 31.2 months in patients with de novo 1q22 gain (p = .04). Median overall survival (OS) from diagnosis was 10.9 years in patients with acquired 1q22 gain, versus 13.0 years in control patients (p = .03) and 6.3 years in patients with de novo 1q22 gain (p = .01). Presence of HR FISH at baseline increased risk of 1q22 gain acquisition. We demonstrate that acquisition of 1q22 gain is a significant molecular event in MM, associated with reduced OS. Among HR patients for whom this clonal evolution is determined, a risk-adapted approach and/or clinical trial should be considered.
引用
- Audil HY, Cook JM, Greipp PT, et al. Prognostic significance of acquired 1q22 gain in multiple myeloma. Am J Hematol. 2021. PMID: 34710241. doi:10.1002/ajh.26391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。